Pages that link to "Q43049571"
Jump to navigation
Jump to search
The following pages link to Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens (Q43049571):
Displaying 30 items.
- Japanese encephalitis-a pathological and clinical perspective (Q21144539) (← links)
- Japanese encephalitis: the virus and vaccines (Q27010434) (← links)
- Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes (Q27469568) (← links)
- The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes (Q27469712) (← links)
- Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form (Q27480299) (← links)
- Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions (Q27480395) (← links)
- Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India (Q33408134) (← links)
- Structures and mechanisms in flavivirus fusion (Q34070126) (← links)
- Japanese encephalitis vaccines: moving away from the mouse brain (Q35194191) (← links)
- Development of a recombinant vaccine against Japanese encephalitis (Q35195483) (← links)
- Flavivirus structure and membrane fusion (Q35616804) (← links)
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer (Q36254081) (← links)
- Japanese encephalitis: development of new candidate vaccines (Q36441519) (← links)
- PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma (Q36764939) (← links)
- Current use and development of vaccines for Japanese encephalitis (Q37032646) (← links)
- Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses (Q37350360) (← links)
- Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice (Q40652637) (← links)
- A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen (Q40788865) (← links)
- Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses (Q41117736) (← links)
- What's going on in vaccine technology? (Q41452212) (← links)
- Recombinant viruses as vaccines and immunological tools (Q41587132) (← links)
- Sub-fragments of the envelope gene are highly protective against the Japanese encephalitis virus lethal infection in DNA priming--protein boosting immunization strategies (Q42982697) (← links)
- Particulate vaccine candidate for Japanese encephalitis induces long-lasting virus-specific memory T lymphocytes in mice (Q42982746) (← links)
- Enhancement of humoral and cellular immunity in mice against Japanese encephalitis virus using a DNA prime-protein boost vaccine strategy (Q42982963) (← links)
- Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates (Q42988555) (← links)
- Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese Encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies (Q42995371) (← links)
- Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model (Q43036724) (← links)
- Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes (Q45751285) (← links)
- Enhanced protective immunity against spring viremia of carp virus infection can be induced by recombinant subunit vaccine conjugated to single-walled carbon nanotubes (Q57132240) (← links)
- Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses (Q64127566) (← links)